Navigation Links
Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
Date:6/12/2012

THOUSAND OAKS, Calif., June 12, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals, a privately held Turkish company. The all-cash transaction significantly expands Amgen's presence in Turkey and the surrounding region, which includes several fast-growing, priority markets for Amgen. The acquisition was initially announced on April 25.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

Contact: Amgen, Thousand Oaks
Mary Klem, 805-447-6979 (US media)
Helen Mills, +41 41 3690 315 (EU media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
8. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
9. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
10. CryoLife Completes Acquisition of Hemosphere
11. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
(Date:6/5/2017)... 5, 2017 Kohll,s Pharmacy & Homecare is the first ... United States . The Raizer is a simple battery ... up to an almost-standing position within a few ... one assistant and does not require any extra effort ... a child can operate it, and lightweight and ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... Maryland’s soybean farmers have improved ... released by the United Soybean Board. , Thanks to the responsible use ... their productivity on less land per bushel, the report says. The United Soybean ...
(Date:6/26/2017)... ... 26, 2017 , ... If the devil is in the ... these days. According to recent estimates, 75 – 80% of the medical bills ... studies point to Electronic Health Records (EHR) with automated features designed to ease ...
(Date:6/25/2017)... Viejo, CA (PRWEB) , ... June 25, 2017 , ... ... any media into an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 ... add film grain for distorted looks, vignettes and blurs to single out subjects, plus ...
(Date:6/25/2017)... ... , ... An increase in wetter weather in the Northern California area naturally ... a humdinger of an allergy season. A relief from drought conditions is most welcome, ... and weed pollen. , “Our patients have been reporting the typical allergy season ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus ... cancer among men in the U.S. and the third most common cause of cancer related ... one man in seven will be diagnosed with prostate cancer during his lifetime. Those ...
Breaking Medicine News(10 mins):